(Q33413609)

English

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Eric Pujade-Lauraine

5

object named as

Eric Pujade-Lauraine

0 references

11

object named as

Gennaro Cormio

1 reference

Europe PubMed Central

26 July 2017

object named as

Caterina Ricci

20

0 references

Claudia Marchetti

object named as

Claudia Marchetti

25

0 references

Pierluigi Benedetti Panici

object named as

Pierluigi Benedetti Panici

10

0 references

Domenica Lorusso

object named as

Domenica Lorusso

24

0 references

Massimo Di Maio

object named as

Massimo Di Maio

29

0 references

object named as

Sandro Pignata

1

0 references

Maria Carmela Piccirillo

28

object named as

Maria Carmela Piccirillo

1 reference

Europe PubMed Central

26 July 2017

Dionyssios Katsaros

3

object named as

Dionyssios Katsaros

1 reference

Europe PubMed Central

26 July 2017

Giovanni Scambia

2

object named as

Giovanni Scambia

1 reference

Europe PubMed Central

26 July 2017

author name string

Ciro Gallo

4

1 reference

Europe PubMed Central

26 July 2017

Sabino De Placido

6

1 reference

Europe PubMed Central

26 July 2017

Alessandra Bologna

7

1 reference

Europe PubMed Central

26 July 2017

Beatrice Weber

8

1 reference

Europe PubMed Central

26 July 2017

Francesco Raspagliesi

9

1 reference

Europe PubMed Central

26 July 2017

Roberto Sorio

12

1 reference

Europe PubMed Central

26 July 2017

Maria Giovanna Cavazzini

13

1 reference

Europe PubMed Central

26 July 2017

Gabriella Ferrandina

14

1 reference

Europe PubMed Central

26 July 2017

Enrico Breda

15

1 reference

Europe PubMed Central

26 July 2017

Viviana Murgia

16

1 reference

Europe PubMed Central

26 July 2017

Cosimo Sacco

17

1 reference

Europe PubMed Central

26 July 2017

Saverio Cinieri

18

1 reference

Europe PubMed Central

26 July 2017

Vanda Salutari

19

1 reference

Europe PubMed Central

26 July 2017

Carmela Pisano

21

1 reference

Europe PubMed Central

26 July 2017

Stefano Greggi

22

1 reference

Europe PubMed Central

26 July 2017

Rossella Lauria

23

1 reference

Europe PubMed Central

26 July 2017

Luigi Selvaggi

26

1 reference

Europe PubMed Central

26 July 2017

Simona Signoriello

27

1 reference

Europe PubMed Central

26 July 2017

Francesco Perrone

30

1 reference

Europe PubMed Central

26 July 2017

Multicentre Italian Trials in Ovarian cancer (MITO-7)

31

1 reference

Europe PubMed Central

26 July 2017

Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO)

32

1 reference

Europe PubMed Central

26 July 2017

Mario Negri Gynecologic Oncology (MaNGO)

33

1 reference

Europe PubMed Central

26 July 2017

European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10)

34

1 reference

Europe PubMed Central

26 July 2017

Gynecologic Cancer InterGroup (GCIG) Investigators

35

1 reference

Europe PubMed Central

26 July 2017

publication date

28 February 2014

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

15

1 reference

Europe PubMed Central

26 July 2017

4

1 reference

Europe PubMed Central

26 July 2017

396-405

1 reference

Europe PubMed Central

26 July 2017

First-line therapy in ovarian cancer trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Population-based differences in treatment outcome following anticancer drug therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970049-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70049-X

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33413609&oldid=2032980467"